BioCorRx bills itself as a developer of "advanced solutions" for alcohol and opioid addictions. But the California-based company has come under fire for plans to test an unapproved naltrexone implant on Louisiana prison inmates and homeless

22 Nov 2019

Philadelphians who are struggling with addiction, in violation of federal laws protecting .

Only one prisoner actually received the implant before the Louisiana Department of Corrections discontinued the testing this spring amid criticism, according to the New Republic. And no homeless Philadelphians have received the implant because BioCorRx has failed to get state approvals, said Mel Wells, president of One Day at a Time, the recovery support organization that BioCorRx enlisted to find subjects.

Screenshot 2019-11-22 At 08.33.37

Still, 33 experts in , bioethics, , and the law on Wednesday petitioned the U.S. Food and Drug Administration to investigate whether BioCorRx conducted an illegal clinical trial. The petition, filed by the consumer advocacy group Public Citizen, also questioned the legality of BioCorRx's use of the naltrexone implant for an unapproved use—weight management.

"The U.S. has a long and troubling history of exploiting prisoners and other vulnerable groups for ," said petition signer Leo Beletsky, Northwestern University professor of law and health sciences. "The apparent clinical trial launched by BioCorRx at the Louisiana State Penitentiary reminds us that even today, we must remain vigilant to prevent such abuses."

Read full story here

Share this on: